We serve Chemical Name:2-Methyl-1,3-thiazole-4-carboxylic acid CAS:35272-15-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Methyl-1,3-thiazole-4-carboxylic acid
CAS.NO:35272-15-2
Synonyms:2-Methyl-4-thiazolecarboxylicAcid;2-Methyl-thiazole-4-carboxylic acid;2-Methyl-4-thiazolecarboxylic acid;2-Methyl-thiazol-4-carbonsaeure;2-Methyl-1,3-thiazole-4-carboxylic acid;4-Thiazolecarboxylic acid, 2-methyl-;2-methyl-4-thiazolcarboxylic acid;4-thiazolecarboxylic acid,2-methyl;F2158-0082;MFCD03407332;2-methylthiazol-4-carboxylic acid;T5N CSJ B1 EVQ
Molecular Formula:C5H5NO2S
Molecular Weight:143.164
HS Code:2934100090
Physical and Chemical Properties:
Melting point:148 °C
Boiling point:301.2±15.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.599
PSA:78.43000
Exact Mass:143.004105
LogP:0.78
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2-Methyl-4-thiazolecarboxylicAcid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,T5N CSJ B1 EVQ physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,T5N CSJ B1 EVQ Use and application,2-Methyl-1,3-thiazole-4-carboxylic acid technical grade,usp/ep/jp grade.
Related News: Alira is one of many in the CRO space to ink deals in recent months. Altasciences acquired preclinical CRO Calvert Laboratories in May, weeks after itself being bought out by Novo Holdings, and a few months after buying early-stage CRO WCCT Global. 2-Methyl-1,3-thiazole-4-carboxylic acid manufacturer The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 2-Methyl-1,3-thiazole-4-carboxylic acid supplier However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. 2-Methyl-1,3-thiazole-4-carboxylic acid vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 2-Methyl-1,3-thiazole-4-carboxylic acid factory However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.
